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To the editor, Essential thrombocythemia (ET) is a clonal hematopoietic stem cell 
neoplasm in which JAK2 (V617F), CALR, and MPL (W515L/K) mutations are the 
most frequent driver mutations[1]. Previous studies demonstrated that most patients 
with ET or primary myelofibrosis (PMF) with JAK2 and MPL-unmutated carry a 
somatic mutation of CALR, the gene encoding calreticulin[2-3]. These CALR 
mutations involve exon 9 and were somatic insertions or deletions (indels). Type-1 
(L367fs*46) and Type-2 (K385fs*47) CALR mutations were the most frequent 
patterns[2-3]. Tefferi et al[1] demonstrated that the favorable prognostic impact of 
CALR mutations may manifest only in persons with Type-1 or Type-1 like mutations 
and that Type-2 or Type-2 like mutations have comparable survival compared with 
JAK2 mutations. However, Rumi et al[4] observed no difference between Type-1 and 
Type-2 CALR mutations. Moreover, there are many CALR point mutations that have 
been reported in recent years, but the role of these point mutations in the molecular 
pathogenesis of myeloproliferative neoplasms (MPN), including ET, is not yet clear. 
Therefore, the prognostic impact of these different types of CALR mutations is still 
controversial[5].  
A 67-year-old woman was referred to our hospital in January 2018 for a 2 weeks 
history of dizziness. Computed Tomography scan confirmed cerebral infarction. 
Laboratory evaluation revealed that white blood cell (WBC) count of 13.8×10
9
/L, 
hemoglobin level of 114 g/L and platelet count of 1159×10
9
/L. Marked 
megakaryocyte hyperplasia in the bone marrow with increased numbers of mature 
megakaryocytes and no dysplasia were observed. Reticulin fibrosis was not observed 
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by Gomori silver staining. Fragment length analysis with subsequent sanger 
sequencing of CALR exon 9 gene confirmed an identical insertion and deletion 
mutations in both biopsies (c.1161_1167delinsGGAAGAA p.D387_D388delinsEE) 
(Figure 1 top) in the absence of JAK2V617F, MPL W515L, and MPL W515K 
mutations. And the CALR mutant allele burden was 36.39%, calculating with the use 
of QuantStudio
TM
 3D digital PCR (Applied Biosystems, America) analysis: % of 
CALR mutant allele burden = (mutated CALR ÷ total CALR) × 100. The BCR/ABL 
fusion gene was negative. Conventional cytogenetic analysis showed 46, XX in all 20 
metaphases (Figure 1 center). Diagnosis of high-risk ET was established on the basis 
of the 2016 World Health Organization (WHO) criteria. The patient has an effective 
response to interferon-alfa-2b with 3 million units twice a week and aspirin for 
subsequent 4 weeks. Her platelet count was well controlled below 400 ×10
9
/L. And 
the CALR mutant allele burden decreased to 6.89% (Figure 1 bottom) in April 2018. 
Up to date, our patient remains asymptomatic and is maintained with interferon 
alfa-2b (3 million units once a week). Her platelet count now averages around 
200–300 ×109/L and has no obvious adverse events.  
A series of studies [2,3,6] have shown that ET with CALR mutations were 
associated with younger age, lower hemoglobin levels and white blood cell counts, 
and higher platelet counts and serum erythropoietin compared with those with JAK2 
(V617F) mutations. In addition, patients with CALR-mutated essential 
thrombocythemia were linked to have a lower risk of thrombosis compared with 
JAK2(V617F)- mutated cases.  
Recently, point mutations in CALR were also reported [7] in follicular 
lymphoma (E403X and E405Q), PMF (E379D) and chronic neutrophilic leukemia 
(E398D). Two rare inframe deletions in CALR exon 9 (p.E393_E395del and 
p.E405del) have been documented in the National Heart, Lung, and Blood Institute 
Grand Opportunity Exome Sequencing Project with undetermined significance. 
Recently, CALR point mutations (E381A and D373M) and inframe deletions 
(E381_A3824A, D397_D4004D, D400_K4014D and E405_V4094V) were also 
detected in patients with suspected MPN and JAK2-mutated MPN in another study 
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albeit with a lower frequency [8]. Using high-resolution melting analysis, Lim KH et 
al [9] revealed several CALR exon 9 alterations were detected in 13 of 59 JAK2 
V617F-mutated ET patients, but none in JAK2/MPL-unmutated ET patients. All of  
these patients harbored the CALR point mutations including: p.E370fs*60, 
p.E371fs*59, p.E381del, p.E371del, p.E378del, p.E396del, p.E374X, p.E380X, 
p.K391X and p.E372G. 
Patients older than 60 years and with cerebral infarction are considered at high 
risk of thrombosis and should be treated with cytoreduction and antiplatelet agents. 
We have confirmed an identical novel insertion and deletion mutations in CALR 
(c.1161_1167del insGGAAGAA p.D387_D388delinsEE) in the current patient with 
JAK2 V617F-unmutated ET. And the CALR mutant allele burden detected by 
QuantStudio
TM
 3D digital PCR analysis further confirmed this result. She has an 
effective response to interferon-alfa-2b treatment. Her platelet count was well 
controlled below 400 ×10
9
/L. And the CALR mutant allele burden decreased to 6.89%. 
Our report and previous results [10-11] suggest that CALR-mutated cells can be 
durably targeted by interferon alfa therapy. 
However, the role of these CALR point mutations in the molecular pathogenesis 
of MPN and other neoplasms is not yet completely clear at the current time. In vitro 
studies on the molecular pathogenesis of CALR mutations in MPN have shown 
controversial results in regard to the activation of the JAK/STAT signaling pathway 
[2-3]. These atypical CALR point mutations, co-occurring with mutations involving 
the JAK-STAT pathway, are thought to play a vital role in the pathogenesis of MPN. 
Further studies of the frequencies of atypical CALR point mutations in ET and other 
neoplasms are needed. 
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Fig.1. The medical information in the patient with essential thrombocythemia. 
Top: Sanger sequencing of the CALR exon 9 hotspot region confirmed an identical 
insertion and deletion mutations in both biopsies (c.1161_1167delinsGGAAGAA 
p.D387_D388delinsEE) (Light blue area). 
Center: The cytogenetic result with 46,XX in all 20 metaphases by conventional 
chromosome techiques in ET. 
Bottom: Evolution of CALR mutation burden during treatment in the patient with ET. 
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